Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2411)	10/13/2008 1:36:20 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ZILAD is now up 13.2% after its earlier dip this morning.<g> Volume is now above its ADV, but it still is far away from the $1 level that it needs for compliance with the NAZ.<g> bigcharts.marketwatch.com ZILAD has discontinued its research and development projects and has implemented “profit enhancement initiatives”.<g> It hired sales representatives to promote its line of oral health and screening tools among dentists.It said that it has "achieved positive cash flow from operations", which was crucial. Bernard

To: Jibacoa who wrote (2411)	10/13/2008 4:59:27 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Looking at XOMA's spike today & trying to answer a question from MJ Today's spike to the $1.60 level(up 33%) on volume of 1,566,145, which was about 1.5x its ADV seems to have been due mainly a reaction to the general market & short covering, since the recent short position was about 11x the ADV, having gone up 4% lately.<g> From the fundamental point of view, things don't look too rosy since it had been trading close to 600xBV, the revenues on the 2ndQ were down 21% & the EL for 2008 is > 300% the $0.10 loss in 2007 Only recent positive thing I remember is that last month it received a contract from the INH for $65M for work on its research on treating botulism poisoning. With the market's change in mood, it is possible that it will test the resistance from Thursday's H at the $1.73 level, but it seems that it will need further short covering to be able to test its more important resistance above the $2 level.<g> bigcharts.marketwatch.com It has further, considerable resistance at the $2.50 level & I doubt it should be able to retest the Oct2007 H of $4.40 this Yr. <g> bigcharts.marketwatch.com Bernard